Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback